Search - tctmd.com

Displaying 441 - 460 of 635

Sort: Relevancy | Date

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Caitlin E. Cox

January 24, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Michael O'Riordan

January 08, 2019

News Daily News

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

Michael O'Riordan

January 03, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Conference News WCC 2018

True Resistant Hypertension Is Prevalent Worldwide

Todd Neale

December 07, 2018

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Less Bivalirudin, Minimal Ultrasound: Survey Highlights Global Transradial Practice Patterns

Michael O'Riordan

November 28, 2018

News Daily News

Bullying or Violence on the Job May Boost CVD Risk

Todd Neale

November 22, 2018

News Daily News

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Caitlin E. Cox

November 21, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

Todd Neale

November 08, 2018

News Daily News

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

Michael O'Riordan

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Advertisement

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Unprotected Left Main PCI? US Interventionalists Aren’t Biting (Yet)

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

Top News in Clinical Cardiology: 2018

True Resistant Hypertension Is Prevalent Worldwide

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Less Bivalirudin, Minimal Ultrasound: Survey Highlights Global Transradial Practice Patterns

Bullying or Violence on the Job May Boost CVD Risk

Obesity Causally Linked to CAD but Not Stroke, Meta-analysis Hints

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Lower Hypertension Range Tied to Heightened CVD Risk in Younger Adults

Low Incidence of A-fib Seen in Elite Athletes, Including Runners and Triathletes

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content